The US-based Dawn Alliance group is planning to set up a United States Food and Drug Administration-approved generic drug manufacturing facility in India.
The company is looking to set up a facility in Vadodara under the aegis of Amkas Laboratories, a firm that already has operations in India.
Dawn Alliance group director Girish Ray said, "We intend to set up a drug manufacturing facility in India, most probably in Vadodara."
The investment size and the drugs, which will be manufactured in Vadodara, have not yet been determined.
The unit would be of international standards and the group is aiming for USFDA approvals.
Industry sources said setting up a generic manufacturing facility would require an investment of Rs 15-25 crore (Rs 150-250 million) and would vary depending on the nature of the products.
Ray said they chose Vadodara because the city was easily accessible from any part of the country. Moreover, Amkas has been operating from Vadodara for the past five years and the group has multiple activities, including business process outsourcing operations, exports of pharma components and sourcing of generics.
Currently, Amkas sources generics through Aurobindo Pharmaceuticals and is in negotiations with other companies in the country.
It also supplies research drug samples to Intas, Alembic, FDC India and Unichem Laboratories, while it supplies over-the-counter drugs to small manufacturers.
Dawn Alliance is headquartered in Glenview, Chicago, and operates a backoffice through Amkas in India.
© 2026